scholarly journals Recurrence Rates in Stable Bipolar Disorder Patients after Drug Discontinuation versus Drug Maintenance: A Systematic Review and Meta-analysis – Corrigendum

2021 ◽  
pp. 1-1
Author(s):  
Taro Kishi ◽  
Yuki Matsuda ◽  
Kenji Sakuma ◽  
Makoto Okuya ◽  
Kazuo Mishima ◽  
...  
2020 ◽  
pp. 1-9
Author(s):  
Taro Kishi ◽  
Yuki Matsuda ◽  
Kenji Sakuma ◽  
Makoto Okuya ◽  
Kazuo Mishima ◽  
...  

Abstract Background This random-effects model meta-analysis of double-blind, randomized placebo-controlled trials compared recurrence rates in bipolar disorder (BD) patients between antipsychotic/mood stabilizer discontinuation and maintenance groups. Methods We conducted systematic literature search of Embase, PubMed, and CENTRAL databases without language restriction from inception until 22 May 2020. Independent investigators assessed studies and extracted data. We calculated risk ratios (RRs) and numbers needed to benefit or harm (NNTB/NNTH). Primary outcome was the recurrence rate of any mood episode at 6 months. Secondary outcomes were recurrence rates of depressive episodes and manic/hypomanic/mixed episodes and all-cause discontinuation at 6 months. We also investigated these outcomes at 1, 3, 9, 12, 18, and 24 months. Results We identified 22 studies (n = 5462) receiving aripiprazole, asenapine, divalproex, long-acting injectable (LAI)-aripiprazole, LAI-risperidone, lamotrigine, lithium, olanzapine, paliperidone, or quetiapine. Mean study duration was 64.50 ± 69.35 weeks. The maintenance group demonstrated lower recurrence rates of any mood episode, depressive episodes, and manic/hypomanic/mixed episodes as well as reduced all-cause discontinuation at every observational point. The RRs (95% confidence interval, NNTB/NNTH) of recurrence rate at 6 months were 0.61 (0.54–0.70, 5) for any mood episode, 0.72 (0.60–0.87, 13) for depressive episodes, and 0.45 (0.36–0.57, 6) for manic/hypomanic/mixed episodes. The RR for all-cause discontinuation at 6 months was 0.71 (0.61–0.82, 6). Conclusions Maintaining drug treatment during clinically stable BD prevented recurrence for up to 24 months. Discontinuation of medications for ⩾1 month significantly increased recurrence risk. However, 47.3% of patients who discontinued drugs for 6 months did not experience recurrence.


2020 ◽  
Vol 125 ◽  
pp. 21-27 ◽  
Author(s):  
Andre Delgado ◽  
Jorge Velosa ◽  
Junyu Zhang ◽  
Serdar M. Dursun ◽  
Flavio Kapczinski ◽  
...  

2018 ◽  
Vol 239 ◽  
pp. 161-170 ◽  
Author(s):  
Norma Verdolini ◽  
Isabella Pacchiarotti ◽  
Cristiano A. Köhler ◽  
Maria Reinares ◽  
Ludovic Samalin ◽  
...  

2018 ◽  
Vol 225 ◽  
pp. 665-670 ◽  
Author(s):  
Luis Ayerbe ◽  
Ivo Forgnone ◽  
Juliet Addo ◽  
Ana Siguero ◽  
Stefano Gelati ◽  
...  

2016 ◽  
Vol 63 ◽  
pp. 327-342 ◽  
Author(s):  
Martino Belvederi Murri ◽  
Davide Prestia ◽  
Valeria Mondelli ◽  
Carmine Pariante ◽  
Sara Patti ◽  
...  

2019 ◽  
Vol 245 ◽  
pp. 812-818 ◽  
Author(s):  
Tien-Yu Chen ◽  
Masoud Kamali ◽  
Che-Sheng Chu ◽  
Chin-Bin Yeh ◽  
San-Yuan Huang ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document